Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 USD | +1.01% | +2.11% | -16.23% |
Jun. 03 | Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating | MT |
Jun. 03 | Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise | MT |
Financials (USD)
Sales 2024 * | 274M | Sales 2025 * | 180M | Capitalization | 1.46B |
---|---|---|---|---|---|
Net income 2024 * | -295M | Net income 2025 * | -399M | EV / Sales 2024 * | 2.9 x |
Net cash position 2024 * | 663M | Net cash position 2025 * | 415M | EV / Sales 2025 * | 5.78 x |
P/E ratio 2024 * |
-4.73
x | P/E ratio 2025 * |
-3.62
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.18% |
Latest transcript on Arcus Biosciences, Inc.
1 day | +1.01% | ||
1 week | +2.11% | ||
Current month | +6.17% | ||
1 month | +1.91% | ||
3 months | -15.83% | ||
6 months | -0.62% | ||
Current year | -16.23% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 14-12-31 |
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 17-09-17 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 15-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 25 M€ | -4.18% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 16 | +1.01% | 498,235 |
24-06-03 | 15.84 | +5.11% | 1,380,134 |
24-05-31 | 15.07 | +0.94% | 640,409 |
24-05-30 | 14.93 | -1.45% | 757,265 |
24-05-29 | 15.15 | -3.32% | 470,551 |
Delayed Quote Nyse, June 04, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.23% | 1.46B | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- RCUS Stock